BMS’s Opdivo/Yervoy Combo Misses PFS Endpoint in Unresectable Stage III NSCLC Trial
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced that a late-stage trial for its checkpoint inhibitors...
FDA Reviews BMS’ Opdivo Subcutaneous Formulation for Broad Indications
The US Food and Drug Administration (FDA) has agreed to review a submission from Bristol-Myers...
BIO Survey Highlights Extensive Dependence on Chinese CDMOs in Life Sciences
The Biotechnology Innovation Organization (BIO), a US industry trade group, has completed a survey among...
Yunnan Baiyao’s Radiopharmaceutical INR101 Advances to Clinical Trial Stage with NMPA Approval
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...
Eisai’s Fycompa Gains New Indication for Generalized Tonic-Clonic Seizures in China
Eisai Co Ltd (TYO: 4523), a Japanese pharmaceutical company, has announced that its antiepilepsy drug...
Ribobay Pharma and General Biol to Commence GMP-Grade Oligonucleotide Manufacturing Services
Shanghai-based contract research, development, and manufacturing organization (CRDMO) Ribobay Pharma has announced plans to commence...
BioSecure Act Advances in US, Aiming to Curb Ties with Chinese Bioscience Firms
US legislators are working expeditiously to finalize the BioSecure Act, legislation that, if enacted, would...
Jacobio Pharma’s KRAS G12C Inhibitor Gains NMPA Approval for Phase III CRC Study
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced that it has...
Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe’s China Subsidiary
Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), a Chinese pharmaceutical company, has announced plans to...
Qilu Pharmaceutical Achieves First Approval for Generic Bendamustine in China
The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic bendamustine,...
Macera Therapeutics and Innorna Co., Ltd Collaborate on CAR-M mRNA-LNP Technology
Macera Therapeutics, a company based in Nanjing specializing in the development of macrophage immunotherapies, has...
Vazyme Biotech and SPH KDL Health Join Forces to Promote Alzheimer’s Blood Tests
Vazyme Biotech Co., Ltd (SHA: 688105), a prominent biotech company based in China, has entered...
Jiangsu BioPerfectus’ Dengue Detection Kit Gains NMPA Approval for Commercialization
Jiangsu BioPerfectus Technologies Co., Ltd (SHA: 688399), a leading in vitro diagnostic (IVD) product manufacturer...
DSciLab, mRNA Pharma Startup, Bags RMB 100 Million in Angel Financing Led by Fosun Health
DSciLab Co., Ltd, a China-based mRNA pharmaceutical company nurtured by Fosun Health Capital, has announced...
Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization
US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter...
Sanofi Secures Novavax Vaccine Tech in a Deal Valued at Up to USD 1.2 Billion
France’s Sanofi (NASDAQ: SNY) has announced a strategic partnership with protein-based vaccines specialist Novavax (NASDAQ:...
China Unveils Sweeping 2024 Legislative Plan with Healthcare and Pharma at Forefront
The State Council of China has released its annual legislative work plan for 2024, outlining...
MSD’s Keytruda Adjuvant Treatment for High-Risk Endometrial Cancer Fails to Meet Primary Endpoint
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...
Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip
Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been...